Characterization of the patient cohort (n = 2502 patients)
. | No. (%) . |
|---|---|
| Type of AML | |
| De novo | 2037 (81.4) |
| s-AML | 281 (11.2) |
| t-AML | 184 (7.4) |
| Total | 2502 (100.0) |
| Cytogenetic subgroup | |
| Normal karyotype | 1198 (48.5) |
| t(15;17) | 102 (4.1) |
| t(8;21) | 132 (5.3) |
| inv(16) | 133 (5.4) |
| 11q23/MLL | 77 (3.1) |
| inv(3)/t(3;3) | 41 (1.7) |
| Complex karyotype,37 typical | 258 (10.4) |
| Complex karyotype,37 atypical | 56 (2.3) |
| Trisomy 8 | 122 (4.9) |
| 5q-/-5 | 24 (1.0) |
| 7q-/-7 | 58 (2.3) |
| Other aberrations | 301 (12.2) |
| Total | 2502 (100.0) |
| FAB subtype | |
| M0 | 94 (4.6) |
| M1 | 365 (17.9) |
| M2 | 750 (36.8) |
| M3 | 62 (3.0) |
| M3v | 32 (1.6) |
| M4 | 343 (16.8) |
| M4eo | 116 (5.7) |
| M5a | 77 (3.7) |
| M5b | 81 (4.0) |
| M6 | 84 (4.1) |
| M7 | 8 (0.4) |
| Not classifiable | 26 (1.3) |
| Total | 2038 (100.0) |
. | No. (%) . |
|---|---|
| Type of AML | |
| De novo | 2037 (81.4) |
| s-AML | 281 (11.2) |
| t-AML | 184 (7.4) |
| Total | 2502 (100.0) |
| Cytogenetic subgroup | |
| Normal karyotype | 1198 (48.5) |
| t(15;17) | 102 (4.1) |
| t(8;21) | 132 (5.3) |
| inv(16) | 133 (5.4) |
| 11q23/MLL | 77 (3.1) |
| inv(3)/t(3;3) | 41 (1.7) |
| Complex karyotype,37 typical | 258 (10.4) |
| Complex karyotype,37 atypical | 56 (2.3) |
| Trisomy 8 | 122 (4.9) |
| 5q-/-5 | 24 (1.0) |
| 7q-/-7 | 58 (2.3) |
| Other aberrations | 301 (12.2) |
| Total | 2502 (100.0) |
| FAB subtype | |
| M0 | 94 (4.6) |
| M1 | 365 (17.9) |
| M2 | 750 (36.8) |
| M3 | 62 (3.0) |
| M3v | 32 (1.6) |
| M4 | 343 (16.8) |
| M4eo | 116 (5.7) |
| M5a | 77 (3.7) |
| M5b | 81 (4.0) |
| M6 | 84 (4.1) |
| M7 | 8 (0.4) |
| Not classifiable | 26 (1.3) |
| Total | 2038 (100.0) |